Want to see HK:6996 full AI Analyst Report?
6996 Stock Chart & Stats
HK$5.27
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$5.27
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$2.76 - HK$8.16
Previous CloseN/A
Volume1.25M
Average Volume (3M)1.49M
Market Cap
HK$2.26B
Enterprise ValueHK$1.68K
Total Cash (Recent Filing)HK$734.29M
Total Debt (Recent Filing)HK$257.51M
Price to Earnings (P/E)38.4
Beta2.17
Next Earnings
Mar 19, 2027EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding679,446,660
10 Day Avg. Volume1,662,282
30 Day Avg. Volume1,488,465
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.32
Price to Sales (P/S)20.24
P/FCF Ratio-11.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.60Price Target Upside101.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.46
Revenue Forecast (FY)HK$810.27M
Bulls Say, Bears Say
Bulls Say
Improving Revenue GrowthThe return to meaningful top-line growth indicates improving commercial traction for approved products and partnerships. Sustained growth could provide operating leverage and broaden the revenue base, although further scale is needed.
Positive Gross ProfitA positive gross margin shows that the company’s products can generate economic value after direct costs. This provides a foundation for future profitability if commercialization expands and operating expenses become more efficient.
Low And Improving LeverageLower leverage reduces fixed financial obligations and preserves flexibility to fund clinical development, regulatory work, and commercialization. This is a structural balance-sheet advantage while the company remains dependent on external capital.
Bears Say
Persistent Operating LossesPersistent operating and net losses show that current commercial scale is insufficient to cover research, development, and corporate costs. Continued losses can constrain investment capacity and increase reliance on financing or partnerships.
Negative Free Cash FlowImproved cash burn is constructive, but materially negative free cash flow means operations are not self-funding. The company must continue using existing capital or obtain new funding to support clinical and commercial programs.
Eroding Capital BaseDeclining equity and assets indicate that accumulated losses are reducing the financial resource base. Unless profitability or external funding improves, this erosion may limit strategic flexibility and weaken resilience across development cycles.
Antengene Corporation Limited News
6996 FAQ
What was Antengene Corporation Limited’s price range in the past 12 months?
Antengene Corporation Limited lowest stock price was HK$2.76 and its highest was HK$8.16 in the past 12 months.
What is Antengene Corporation Limited’s market cap?
Antengene Corporation Limited’s market cap is HK$2.26B.
When is Antengene Corporation Limited’s upcoming earnings report date?
Antengene Corporation Limited’s upcoming earnings report date is Mar 19, 2027 which is in 196 days.
How were Antengene Corporation Limited’s earnings last quarter?
Antengene Corporation Limited released its earnings results on Aug 21, 2026. The company reported HK$0.397 earnings per share for the quarter, missing the consensus estimate of HK$0.432 by -HK$0.035.
Is Antengene Corporation Limited overvalued?
According to Wall Street analysts Antengene Corporation Limited’s price is currently Undervalued.
Does Antengene Corporation Limited pay dividends?
Antengene Corporation Limited does not currently pay dividends.
What is Antengene Corporation Limited’s EPS estimate?
Antengene Corporation Limited’s EPS estimate is 0.22.
How many shares outstanding does Antengene Corporation Limited have?
Antengene Corporation Limited has 679,446,660 shares outstanding.
What happened to Antengene Corporation Limited’s price movement after its last earnings report?
Antengene Corporation Limited reported an EPS of HK$0.397 in its last earnings report, missing expectations of HK$0.432. Following the earnings report the stock price went down -2.861%.
Which hedge fund is a major shareholder of Antengene Corporation Limited?
Currently, no hedge funds are holding shares in HK:6996
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Antengene Corporation Limited
Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-016, a next-generation XPO1 inhibitor, is currently undergoing Phase I/II clinical trials for individuals with solid tumors. ATG-527 (Verdinexor) has successfully completed its Phase I evaluation for chronic human viral infections. The company is also advancing ATG-019, a dual PAK4/NAMPT inhibitor targeting non-Hodgkin's lymphoma and advanced solid tumors, and ATG-017, an ERK1/2 inhibitor designed for treating advanced solid tumors and hematologic malignancies. Additionally, ATG-010 (selinexor) is a SINE compound that modulates XPO1. ATG-101, a bispecific PD-L1/4-1BB antibody, is in Phase I studies for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Completing its clinical-stage assets is ATG-008 (onatasertib), an orally delivered mTOR kinase inhibitor aimed at solid tumors exhibiting specific genetic alterations like NFE2L2, STK11, and RICTOR. In its earlier, pre-clinical research phase, Antengene is exploring ATG-037, a CD73 inhibitor for advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031, a CD24 antibody; ATG-027, a B7H3/PD-L1 bispecific antibody; ATG-032, a LILRB antibody; and ATG-041, an Axl-Mer inhibitor. Founded in 2016, the company maintains its headquarters in Shanghai, China.
6996 Stock 12 Month Forecast
Average Price Target
HK$10.60
▲(101.14% Upside)
Technical Analysis
Innovent Biologics
―
Alphamab Oncology
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―